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(57) ABSTRACT 
The invention relates to sesquiterpene synthases and methods 
for their production and use. Particularly, the invention pro-
vides nucleic acids comprising the nucleotide sequence of 
citrus valencene synthase (CVS) which codes for at least one 
CVS. The invention further provides nucleic acids compris-
ing the nucleotide sequence coding for amino acid residues 
forming the tier 1 and tier 2 domains ofCVS. The invention 
also provides for methods of making and using the nucleic 
acids and amino acids of the current invention. 
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Nucleotide (DNA) sequence for Citrus Valencene Synthase gene (CVS) 
SEQ ID NO.: 1 
Length: 1710 nt 
64 atgtcgtctggagaaacatttcgtcctactgcagatttccatcct 
109 agtttatggagaaaccatttcctcaaaggtgcttctgatttcaag 
154 acagttgatcatactgcaactcaagaacgacacgaggcactgaaa 
199 gaagaggtaaggagaatgataacagatgctgaagataagcctgtt 
244 cagaagttacgcttgattgatgaagtacaacgcctgggggtggct 
269 tatcactttgagaaagaaatagaagatgcaatactaaaattatgt 
334 ccaatctatattgacagtaatagagctgatctccacaccgtttcc 
379 cttcattttcgattgcttaggcagcaaggaatcaagatttcatgt 
424 gatgtgtttgagaagttcaaagatgatgagggtagattcaagtca 
469 tcgttgataaacgatgttcaagggatgttaagtttgtacgaggca 
514 gcatacatggcagttcgcggagaacatatattagatgaagccatt 
559 gctttcactaccactcacctgaagtcattggtagctcaggatcat 
604 gtaacccctaagcttgcggaacagataaatcatgctttataccgt 
649 cctcttcgtaaaaccctaccaagattagaggcgaggtattttatg 
694 tccatgatcaattcaacaagtgatcatttatacaataaaactctg 
739 ctgaattttgcaaagttagattttaacatattgctagagccgcac 
784 aaggaggaactcaatgaattaacaaagtggtggaaagatttagac 
829 ttcactacaaaactaccttatgcaagagacagattagtggagtta 
874 tatttttgggatttagggacatacttcgagcctcaatatgcattt 
919 gggagaaagataatgacccaattaaattacatattatccatcata 
964 gatgatacttatgatgcgtatggtacacttgaagaactcagcctc 
1009 tttactgaagcagttcaaagatggaatattgaggccgtagatatg 
1054 cttccagaatacatgaaattgatttacaggacactcttagatgct 
1099 tttaatgaaattgaggaagatatggccaagcaaggaagatcacac 
1144 tgcgtacgttatgcaaaagaggagaatcaaaaagtaattggagca 
1189 tactctgttcaagccaaatggttcagtgaaggttacgttccaaca 
1234 attgaggagtatatgcctattgcactaacaagttgtgcttacaca 
1279 ttcgtcataacaaattccttccttggcatgggtgattttgcaact 
1324 aaagaggtttttgaatggatctccaataaccctaaggttgtaaaa 
1369 gcagcatcagttatctgcagactcatggatgacatgcaaggtcat 
1414 gagtttgagcagaagagaggacatgttgcgtcagctattgaatgt 
1459 tacacgaagcagcatggtgtctctaaggaagaggcaattaaaatg 
1504 tttgaagaagaagttgcaaatgcatggaaagatattaacgaggag 
1549 ttgatgatgaagccaaccgtcgttgcccgaccactgctcgggacg 
1594 attcttaatcttgctcgtgcaattgattttatttacaaagaggac 
1639 gacggctatacgcattcttacctaattaaagatcaaattgcttct 
1684 gtgctaggagaccacgttccattttga 1710 
FIG. 5 
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Amino acid sequence of Citrus Valencene Synthase (CVS) 
SEQ ID NO.: 4 
Length: 548 aa 
1 M S S 
16 S L W 
31 T V D 
46 E E V 
61 Q K L 
76 y 
91 p 
106 L 
121 D 
136 s 
151 A 
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Absolute SEQ ID NO 4 Comparative SEQ ID NO 7 Nucleotide SEQ ID NO.: 5 
-··· 
R264 R264 853aga 
W273 W273 880ttg 
A403 A403 1270gct 
Y404 Y404 1273tac 
C441 C440 1384tcg 
D445 D444 1396gat 
Y522 Y520 1627tac 
D526 D525 1639gac 
Y528 Y527 1645tat 
T529 T528 1648acg 
.. , .. --------·-
FIG. 12 
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Absolute SEQ ID NO 4 Comparative SEQ ID NO 8 SEQIDNO.: 6 
Fl3 F20 lOOttc 
R266 R266 859aga 
L270 L270 871tta 
8298 S298 955tcc 
D302 D302 967gat 
·---- ·······-·----
V372 V372 1177gta 
Y376 Y376 11 S9tac 
S401 8401 1264agt 
C402 C402 1267tgt 
V407 V407 1282gtc 
A437 A436 1372gca 
R442 R441 1387aga 
D446 D445 l399gac 
.. -.-
G449 G448 1408ggt 
L514 L512 1603ctt 
A517 A515 1612gca 
15lll I516 1615att 
1521 I519 1624att 
H530 H529 
! 
1651cat i 
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MASAAVANYEEEIVRPVADFSPSLWGDQFLS--FSIKNQVF~KYAQEIEA 43 
MSSG------ -ETFRPTADFHPSLWRNHFLKGASDFKTVDHTATQERHEA 43 
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TEAS Amino Acid Number CVS Absolute Comparative 
SEQIDN0.:4 SEQ ID NOS 7 and 8 
TIERl 
R264 R264 R264 
W273 W273 W273 
.. ----
T403 A403 A403 
Y404 Y404 Y404 
C440 C441 C440 
D444 D445 D444 
Y520 Y522 Y520 
D525 D526 D525 
Y527 Y528 Y527 
T528 T529 T528 
--·-·· - - ---·--
TIER2 
F20 F13 F20 
R266 R266 R266 
C270 L270 L270 
S298 S298 S298 
D302 D302 D302 
V372 V372 V372 
Y376 Y376 t Y376 
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T401 S401 S401 
----··· ····-------
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D445 D446 D445 
T448 G449 G448 
L512 L514 L512 
1515 A517 A515 
V516 !518 1516 
T519 1521 1519 
H529 H530 H529 
FIG. 17 
US 7,442,785 B2 
1 
SESQUITERPENE SYNTHASE GENE AND 
PROTEIN 
RELATED APPLICATION 
Benefitofpriorityunder35 U.S.C. 119(e) is claimed herein 
to U.S. Provisional Application No. 60/4S9,514, filed Jul. 24, 
2003. The disclosure of the above referenced application is 
incorporated by reference in its entirety herein. 
2 
Rich, in U.S. Pat. No. 4,973,4S5, discloses a method of 
producing aqueous orange stripper essences and orange strip-
per oils with high ratios of valencene to the less desirable 
orange flavor compounds. This procedure involves the fol-
lowing steps: (a) heating an orange fed juice stream to a 
temperature of3 7.7° C. to 71 o C.; (b) stripping the heated feed 
juice with steam at a steam: soluble solids ratio of0.3 to 1.5, 
at a temperature of 37.7° C. to 71 o C. and at a stripping 
column pressure of less than 9 inches of Hg, absolute; (c) 
FIELD OF THE INVENTION 
This invention relates generally to the field of production of 
valencene and nootkatone, and more particularly relates to 
the discovery of a valencene synthase gene and related pro-
tein, which provides a pathway for generating highly pure 
valencene which can be converted into the flavorant, nootka-
tone. 
10 condensing the stripped volatiles at a temperature of 40.6° C. 
to -196° C.; (d) centrifuging the condensate in a continuous 
stacked disk hermetic centrifuge to produce two clear phases; 
and (e) removing the aqueous orange stripper essence phase. 
In U.S. Pat. No. 5,260,0S6 Downton eta!. describe a pro-
15 cess for making an aseptic citrus sensible pulp/juice slurry by 
extracting and removing juice from citrus juice containing 
sensible pulp. After this process is complete, flavorants, such 
as valencene are added to make up for those that are lost 
BACKGROUND 
Terpenes are a diverse family of compounds with carbon 
skeletons composed of five-carbon isoprene units. Approxi-
mately 20,000 different terpenes and terpenoids (compounds 
20 
of terpene origin whose carbon skeleton has been altered or 
rearranged) have been identified to date, representing only a 25 
small fraction of the estimated natural variation. Terpenes are 
commonly isolated from the essential oils of plants. Essential 
oils often have pleasant tastes or aromas, and they are widely 
used as flavorings, deodorants, and medicines. 
Sesquiterpenes are terpenes with 15 carbon atoms (three 30 
isoprene units). The plant kingdom contains the highest diver-
sity of sesquiterpenes. Often they play a role in defense of the 
plants against pathogens, insects and herbivores and for 
attraction of pollinating insects. 
Valencene (1 ,2,3, 5, 6, 7, S, Sa -octahydro-7-isopropenyl-1, 35 
Sa-dimethyl-naphthalene) and nootkatone (4,4a,5,6,7,S-
hexahydro-6-isopropeny l-4,4a -dimethy 1-2(3 H)-naphtal-
enone) are just two examples of sesquiterpenes that are 
derived from cyclization of the ubiquitous pyrophosphate 
intermediate farnesyl diphosphate. Nootkatone is formed by 40 
the oxidation ofvalencene. 
during this extraction process. 
Hiramoto eta!., in U.S. Pat. No. 6,495,193 prepares a citrus 
flavor from a low-boiling part of a cold pressed oil by a 
hydrate alcohol solvent extraction. To maintain the stability 
of the flavor, a stabilizing coumarin analogue component is 
added. 
In a US Patent Application, publication number US 
200301S5956, Gradley claims a separation method for 
extracting desired sesquiterpene aroma compounds, such as 
valencene and nootkatone, from an aqueous phase by sepa-
rating the aqueous mixture from a water-immiscible hydro-
phobic phase by means of a hydrophilic membrane and allow-
ing the desired components to move out off the aqueous phase 
through the membrane and into the hydrophobic phase. 
Kotachi eta!., in US Patent Application, publication num-
ber 20030203090, teaches of a process for preparing orange 
oil useful as fragrance or flavor material, by mixing raw 
material oil containing valencene with a high-boiling solvent 
having a boiling point exceeding 240° C. under normal pres-
sure, to give a mixture, and fractionally distilling the mixture 
obtained. 
N ootkatone is a high demand, high value flavorant added to 
many of the commercial soft drinks sold worldwide. Cur-
rently, the practice of extracting nootkatone from citrus pulp 
and rind is considered an expensive and somewhat unreliable 
process. Nootkatone can be synthesized by the oxidation of 
Valencene and nootkatone are compounds of natural ori-
gin, and are natural constituents of citrus oils, such as orange 
and grapefruit. Because of its excellent organoleptic qualities 
and in particular its typical grapefruit taste, nootkatone is a 
widely used ingredient in perfumery and the flavor industry. 
Alternatively, nootkatone may be used as an insecticide. 
Valencene, the starting material for the generation of nootka-
tone (either biologically or chemically), is also used as a 
flavorant and fragrance. 
45 valencene. The valencene starting material is expensive and is 
easily degraded during evaporative heat concentration pro-
cesses typically used to remove the bulk of water from the 
feed juice. Thus, current methods to purify valencene from 
citrus fruits are costly, difficult, and are limited by what the 
Several methods to purifY sesquiterpenes, such as valen-
cene and nootkatone, from citrus fruits or to maintain high 
levels of these sesquiterpenes in citrus fruit extracts have been 
described in the prior art. These methods are described below. 
50 fruit can deliver. Moreover, such methods are vulnerable to 
interruptions in the supply of citrus fruits, which is dependent 
on the weather. A frost or hailstorm in a major citrus fruit 
growing region such as Florida can interrupt the supply. Fur-
thermore, methods to produce nootkatone that consume 
Japikse eta!., in U.S. Pat. No. 4,693,905, claimed a method 55 valencene are quite costly, and thus not commercially desir-
able. Therefore, there is a need for an alternative means for 
preparing valencene and nootkatone. 
of extracting concentrated orange flavor and aroma compo-
sitions from natural orange essence oil by using a dense 
solvent gas. Their procedure entailed (a) contacting natural 
orange essence oil with a solvent gas having a temperature 
between its critical temperature and 100° C., and having a 60 
reduced pressure between about 0.56 and about 1.31 (where 
reduced pressure is defined as the extraction pressure of the 
solvent gas divided by its critical pressure), to extract flavor 
and aroma compounds; (b) separating the solvent gas and 
dissolved compounds from the remaining undissolved com- 65 
pounds; and (c) separating the dissolved compounds from the 
solvent gas. 
SUMMARY OF THE INVENTION 
In one embodiment, the invention relates to isolated 
nucleic acids that encode a sesquiterpene synthase. The 
invention provides an isolated nucleic acid selected from: (a) 
a nucleic acid comprising the nucleotide sequence substan-
tially as set out in SEQ ID NO: 1; (b) a nucleic acid encoding 
the polypeptide substantially set out in SEQ ID NO: 4; and (c) 
a nucleic acid that hybridizes to the nucleic acid of (a) or (b) 
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under low stringency conditions, wherein the polypetide 
encoded by said nucleic acid is a sesquiterpene synthase. 
Other embodiments include: a polypeptide encoded by a 
nucleic acid of the invention; a host cell comprising a nucleic 
acid of the invention; a non-human organism modified to 
harbor a nucleic acid of the invention; and methods of pro-
ducing a polypeptide comprising culturing host cells of the 
invention. 
In another embodiment, the invention provides an isolated 
polypeptide comprising an amino acid sequence substantially 10 
as set out in SEQ ID NO: 4. 
In a further embodiment, the invention provides a vector 
comprising at least one nucleic acid chosen from (a) a nucleic 
acid comprising the nucleotide sequence substantially as set 
out in SEQ ID NO: 1; (b) a nucleic acid encoding the polypep- 15 
tide substantially set out in SEQ ID NO: 4; and (c) a nucleic 
acid that hybridizes to the nucleic acid of(a) or (b) under low 
stringency conditions, wherein the polypetide encoded by 
said nucleic acid is a sesquiterpene synthase. Other embodi-
ments include, methods of making a recombinant host cell 20 
comprising introducing a vector of the invention into a host 
cell. 
In a further embodiment, the invention relates to isolated 
nucleic acids that encode a sesquiterpene synthase. The 
invention provides an isolated nucleic acid selected from: (a) 25 
a nucleic acid comprising the nucleotide sequence substan-
tially as set out in SEQ ID NO: 5 or SEQ ID NO.: 6; (b) a 
nucleic acid encoding the polypeptide substantially set out in 
SEQ ID NO: 7 or SEQ ID NO.: 8; and (c) a nucleic acid that 
hybridizes to the nucleic acid of (a) or (b) under low strin- 30 
gency conditions, wherein the polypetide encoded by said 
nucleic acid is a sesquiterpene synthase. Other embodiments 
include: a polypeptide encoded by a nucleic acid of the inven-
tion; a host cell comprising a nucleic acid of the invention; a 
non-human organism modified to harbor a nucleic acid of the 35 
invention; and methods of producing a polypeptide compris-
ing culturing host cells of the invention. 
4 
In another embodiment the invention provides a method of 
making at least one terpenoid comprising: 
1) contacting at least one acyclic pyrophosphate terpene pre-
cursor with at least one polypeptide encoded by a nucleic 
acid of the current invention. In one embodiment, the 
nucleic acid is chosen from (a) a nucleic acid comprising 
the nucleotide sequence substantially as set out in SEQ ID 
NO.: 1, SEQIDNO.: 5 orSEQIDNO.: 6; (b)anucleicacid 
encoding the polypeptide substantially set out in SEQ ID 
NO: 4, SEQ ID NO.: 7 or SEQ ID NO.: 8; and (c) a nucleic 
acid that hybridizes to the nucleic acid of (a) or (b) under 
low stringency conditions, wherein the polypetide encoded 
by said nucleic acid is a sesquiterpene synthase, 
2) isolating at least one terpenoid produced in 1). 
In one embodiment, the at least one terpenoid is chosen 
from the group consisting of sesquiterpene. 
In a further embodiment, the at least one acyclic pyrophos-
phate terpene precursor is famesyl-diphosphate (FPP). The 
sesquiterpene produced by the methods of the invention 
include, but are not limited to, valencene, valencene deriva-
tives, valencene fragments, and compounds having the citrus 
valencene carbon skeleton. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shows the conversion of FPP to the sesquiterpene 
reaction products 5-epi-aristolochene, prenmaspirodiene and 
valencene catalyzed by Nicotiana tabacum epi-aristolochene 
synthase (TEAS), Hyoscyamus muticus prenmaspirodiene 
synthase (HPS), and Citrus paradisi valencene synthase 
(CVS), respectively. 
FIG. 2 illustrates a mechanism for the enzyme catalyzed 
development of regia- and enantio-specificity in eremo-
philanes. Upon loss of the diphosphate from C1 and genera-
tion of the initial carbocation, a chiral center arises from the 
first attack on either the si or re face of sp2 hybridized C10 
yielding either (1 OR)-germacrene A or (1 OS)-germacrene A. 
Two additional chiral centers develop upon formation of an In another embodiment, the invention provides an isolated 
polypeptide comprising an amino acid sequence substantially 
as set out in SEQ ID NO: 7 or SEQ ID NO.: 8. 
In a further embodiment, the invention provides a vector 
comprising nucleic acid chosen from (a) a nucleic acid com-
prising the nucleotide sequence substantially as set out in 
SEQ ID NO: 5 or SEQ ID NO.: 6; (b) a nucleic acid encoding 
the polypeptide substantially set out in SEQ ID NO: 7 or SEQ 
ID NO.: 8; and (c) a nucleic acid that hybridizes to the nucleic 
acid of (a) or (b) under low stringency conditions, wherein the 
polypetide encoded by said nucleic acid is a sesquiterpene 
synthase. Other embodiments include, methods of making a 
recombinant host cell comprising introducing a vector of the 
invention into a host cell. 
40 internal bond between C2 and C7. This process of proton-
initiated, internal cyclization (illustrated as transition states) 
requires that the p-orbitals of sp2 hybridized C2 and C7 face 
and align with each other. The 4 possible combinations of 
overlapping orbitals are dependent on the orientation of the 
In one embodiment, the invention provides a method of 
making at least one sesquiterpene synthase comprising cul-
turing a host cell modified to contain at least one nucleic acid 
sequence under conditions conducive to the production of 
said at least one sesquiterpene synthase. In one embodiment, 
the at least one nucleic acid is chosen from (a) a nucleic acid 
comprising the nucleotide sequence substantially as set out in 
SEQ ID NO: 1, SEQ ID NO.: 5 or SEQ ID NO.: 6; (b) a 
nucleic acid encoding the polypeptide substantially set out in 
SEQ ID NO: 4, SEQ ID NO.: 7 or SEQ ID NO.: 8; and (c) a 
nucleic acid that hybridizes to the nucleic acid of (a) or (b) 
under low stringency conditions, wherein the polypetide 
encoded by said nucleic acid is a sesquiterpene synthase. The 
host may be chosen from, for example, plants, microorgan-
isms, bacterial cells, yeast cells, plant cells, and animal cells. 
45 respective p orbitals either above or below the plane of the 
eudesmalyl carbocation intermediate. The possible re and si 
orientations of the C2 p-orbitals are given on the vertical axis 
of the diagram and those for C7 depicted on the horizontal 
axis. These orientations direct the stereochemistry of the 
50 ensuing methyl migrations and hydride shifts (not illustrated) 
and define, as a consequence, the final chirality of the methyl 
substitutions at C2 and C3. Subsequent to these rearrange-
ments, a tertiary carbocation centered at C7 is formed (an 
eremophilyl cation, not shown) and alternate elimination of a 
55 proton from C6 or C8 give two subclasses of double bond 
regioisomers, illustrated as layers. Known eremophilanes are 
noted by their common name. 
FIG. 3 illustrates a proposed pathway for the biosynthesis 
of nootkatone in citrus. The scheme suggests at least two 
60 steps, the first step is catalyzed by the sesquiterpene synthase 
of the current invention, denoted as "1" in the figure, which 
leads to the production of valencene and the second step 
consisting of a regia-specific hydroxylation, followed by oxi-
dation. The second step could be catalyzed by a single mul-
65 tifunctional hydroxylase or could involve sequential enzyme 
mediated reactions, and which are denoted as "2" in the 
figure. 
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FIG. 4 illustrates a sequence alignment of amino acids 
lining the active site (1st tier) and those within 3 A of the 
active site residues (2nd tier) ofTEAS with the corresponding 
positions of CVS. For uniformity, the TEAS amino acids 
numbering was used, and thus the corresponding CVS amino 
acids renumbered-termed comparative numbering. The 1st 
tier residues lie within 3 A of a substrate analog co-crystal-
lized within the TEAS enzyme and includes residues making 
6 
FIG. 15a shows the absolute amino acid sequence from 
SEQ ID NO.: 4 corresponding to Tier 2 amino acid residues. 
FIG. 15b shows the comparative amino acid sequence of the 
Tier 2 amino acid residues (SEQ ID NO.: 8). 
FIG. 16 is a sequence alignment of the amino acid 
sequence of TEAS active site compared to the amino acid 
sequence of the CVS active site. The alignment maximizes 
residue similarities and introduce gaps where necessary. 
Absolute amino acid numbering is shown for CVS, thus up the J/K loop which clamps down over the active site upon 
substrate binding. The corresponding residues within CVS 
(valencene synthase) were initially identified by primary 
sequence alignment, then visual inspection of the relevant 
CVS sequences overlaid on the TEAS 3-dimensional struc-
ture. Residues different from TEAS are highlighted. 
10 amino acid numbering from SEQ ID NO.: 4 is shown for 
cvs. 
FIG. 5 shows SEQ ID NO.: 1, which is the DNA sequence 15 
for the citrus valencene synthase gene from Citrus paradis 
isolated in the current invention. 
FIG. 6 shows SEQ ID NO.: 4, which is the protein sequence 
for the citrus valencene synthase from Citrus paradisi. 
FIG. 17 is a chart showing the TEAS Tier 1 and Tier 2 
amino acid residues in colnmn 1; the CVS Tier 1 and Tier 2 
amino acid residues with absolute numbering in colunm 2; 
and the CVS Tier 1 and Tier 2 amino acid residues with 
comparative numbering in colunm 3. 
DETAILED DESCRIPTION OF THE INVENTION 
20 
Abbreviations and Terms 
FIG. 7 illustrates reaction product analysis of citrus valen-
cene synthase (CVS) incubated at pH 7.5. Lysate of E. coli 
expressing the CVS eDNA was incubated with FPP at pH 7.5 
and total pentane extractable products evaluated by GC-MS 
(upper panel). The mass spectrum of the reaction product 
corresponding to peak A (middle panel) is compared to that of 25 
authentic valencene in the lower panel. The mass spectrum of 
peak B is identical to that for beta-elemene, the thermal-
induced rearrangement product of germacrene A. 
FIG. 8 illustrates a mass spectrum for the peak with a 
retention time of7.38 minutes from FIG. 7 (top) compared to 30 
the spectra for beta-elemene published by the NIST library 
(bottom). 
In accordance with the present invention and as used 
herein, the following terms and abbreviations are defined with 
the following meanings, unless explicitly stated otherwise. 
These explanations are intended to be exemplary only. They 
are not intended to limit the terms as they are described or 
referred to throughout the specification. Rather, these expla-
nations are meant to include any additional aspects and/or 
examples of the terms as described and claimed herein. 
The following abbreviations are used herein: 
As used herein, a "derivative" is any compound obtained 
from a known or hypothetical compound and containing 
essential elements of the parent substance. 
The phrase "substantially identical" means that a relevant 
FIG. 9 illustrates mass spectrum for the peak with a reten-
tion time of 8.89 in FIG. 7 (top) compared to that for valen-
cene purchased from Fluka Chemical Company (bottom). 35 sequence is at least 70%, 75%, 80%, 85%, 90%, 92%, 95% 
96%, 97%, 98%, or 99% identical to a given sequence. By 
way of example, such sequences may be allelic variants, 
sequences derived from various species, or they may be 
FIG. 10 illustrates that the reaction product specificity of 
citrus valencene synthase (CVS) is pH dependent. Partially 
purified synthase isolated from E. coli expressing the CVS 
eDNA was incubated with FPP at the indicated pH values and 
ethylacetate extracts were examined directly by GC-MS. 40 
Absolute values for valencene (solid symbols) and germa-
crene A (measured as the thermally rearranged product ~-el­
emene) (open symbols) are reported and represent greater 
than 95% of the total reaction products at all pHs. 
FIG. 11 is a sequence alignment of amino acids lining the 45 
active site (1 sttier) ofTEAS with the corresponding positions 
derived from the given sequence by truncation, deletion, 
amino acid substitution or addition. Percent identity between 
two sequences is determined by standard alignment algo-
rithms such as ClustalX when the two sequences are in best 
alignment according to the alignment algorithm. 
As used herein, the term "hybridization" or "hybridizes" 
under certain conditions is intended to describe conditions for 
hybridization and washes under which nucleotide sequences 
that are significantly identical or homologous to each other 
remain bound to each other. Appropriate hybridization con-
ditions can be selected by those skilled in the art with minimal 
of HPS and CVS. The 1 st tier residues lie within 3 A of a 
substrate analog co-crystallized within the TEAS enzyme and 
includes residues making up the J/K loop which clamps down 
over the active site upon substrate binding. The correspond-
ing residues within the other terpene synthases were initially 
identified by primary sequence alignment, then visual inspec-
tion of the relevant sequences overlaid on the TEAS 3-dimen-
sional structure. Residues in CVS differing from TEAS are 
highlighted. 
50 experimentation as exemplified inAusubel, F. A., eta!., eds., 
Current Protocols in Molecular Biology Vol. 2, John Wiley 
and Sons, Inc., New York (1995). Additionally, stringency 
conditions are described in Sam brook eta!. Molecular Clon-
ing: A Laboratory Manual, 2nd ed., Cold Spring Harbor 
FIG.12 shows SEQ ID NO.: 5, which is the DNA sequence 
from SEQ ID NO.: 1 corresponding to the amino acids form-
ing Tier 1. Comparative numbering from Tier 1 amino acid 
residues is also shown (SEQ ID NO.: 7). 
55 Laboratory Press, New York (1989). Variations on the condi-
tions for low, moderate, and high stringency are well known 
in the art and may be used with the current invention. 
FIG.13 shows SEQ ID NO.: 6, which is the DNA sequence 60 
from SEQ ID NO.: 1 corresponding to the amino acids form-
ing Tier 2. Comparative numbering from Tier 2 amino acid 
residues is also shown (SEQ ID NO.: 8). 
FIG. 14a shows the absolute amino acid sequence from 
SEQ ID NO.: 4 corresponding to the Tier 1 amino acid resi- 65 
dues. FIG. 14b shows the comparative amino acid sequence 
of the Tier 1 amino acid residues (SEQ ID NO.: 7) 
The terms "nucleic acid" or "nucleic acid molecule" refer 
to a deoxyribonucleotide or ribonucleotide polymer in either 
single-or double-stranded form, and unless otherwise lim-
ited, would encompass known analogs of natural nucleotides 
that can function in a similar manner as naturally occurring 
nucleotides. A "nucleotide sequence" also refers to a poly-
nucleotide molecule or oligonucleotide molecule in the form 
of a separate fragment or as a component of a larger nucleic 
acid. The nucleotide sequence or molecule may also be 
referred to as a "nucleotide probe." Some of the nucleic acid 
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sequences of the invention. Alternatively, a polypeptide 
within the scope of the invention is recognized by an antibody 
that specifically recognizes any peptide encoded by the 
nucleic acid sequences of the invention. Antibodies are 
defined to be specifically binding if they bind polypeptides of 
the invention with a Ka of greater than or equal to about 1 0 7 
M- 1 , such as greaterthanorequal to 108 M- 1 .As used herein, 
the term "isolated," in reference to polypeptides or proteins, 
means that the polypeptide or protein is substantially 
molecules of the invention are derived from DNA or RNA 
isolated at least once in substantially pure form and in a 
quantity or concentration enabling identification, manipula-
tion, and recovery of its component nucleotide sequence by 
standard biochemical methods. Examples of such methods, 
including methods for PCR protocols that may be used 
herein, are disclosed in Sambrook eta!. Molecular Cloning: A 
Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory 
Press, New York (1989), Ausubel, F. A., eta!., eds., Current 
Protocols in Molecular Biology, John Wiley and Sons, Inc., 
New York (1987), and Innis, M., eta!. (Eds.) PCR Protocols: 
A Guide to Methods and Applications, Academic Press, San 
Diego, Calif. (1990). Reference to a nucleic acid molecule 
also includes its complement as determined by the standard 
Watson-Crick base-pairing rules, with uracil (U) in RNA 
replacing thymine (T) in DNA, unless the complement is 
specifically excluded. 
10 removed from polypeptides, proteins, nucleic acids, or other 
macromolecules with which it, or its analogues, occurs in 
nature. Although the term "isolated" is not intended to require 
a specific degree of purity, typically, the protein will be at least 
about 75% pure, more typically at least about 90% pure, 
15 preferably at least about 95% pure, and more preferably at 
least about 99% pure. 
A polypeptide "variant" as referred to herein means a 
polypeptide substantially homologous to a native polypep-
tide, but which has an amino acid sequence different from that 
As described herein, the nucleic acid molecules of the 
invention include DNA in both single-stranded and double-
stranded form, as well as the DNA or RNA complement 
thereof. DNA includes, for example, DNA, genomic DNA, 
chemically synthesized DNA, DNA amplified by PCR, and 
combinations thereof. Genomic DNA, including translated, 
non-translated and control regions, may be isolated by con-
ventional techniques, e.g., using any one of the cDNAs of the 
invention, or suitable fragments thereof, as a probe, to iden-
tify a piece of genomic DNA which can then be cloned using 
methods commonly known in the art. 
20 encoded by any of the nucleic acid sequences of the invention 
because of one or more deletions, insertions or substitutions. 
Variants can comprise conservatively substituted sequences, 
meaning that a given amino acid residue is replaced by a 
residue having similar physiochemical characteristics. See 
Polypeptides encoded by the nucleic acids of the invention 
are encompassed by the invention. As used herein, reference 
to a nucleic acid "encoding" a protein or polypeptide encom-
passes not only cDNAs and other intronless nucleic acids, but 
also DNAs, such as genomic DNA, with introns, on the 
assumption that the introns included have appropriate splice 
donor and acceptor sites that will ensure that the introns are 
spliced out of the corresponding transcript when the tran-
script is processed in a eukaryotic cell. Due to the degeneracy 
25 Zubay, Biochemistry, Addison-Wesley Pub. Co., (1983). It is 
a well-established principle of protein and peptide chemistry 
that certain amino acids substitutions, entitled "conservative" 
amino acid substitutions, can frequently be made in a protein 
or a peptide without altering either the confirmation or the 
30 function of the protein or peptide. Such changes include 
substituting any of isoleucine (I), valine (V), and leucine (L) 
for any other of these amino acids; aspartic acid (D) for 
glutamic acid (E) and vice versa; glutamine (Q) for aspar-
agine (N) and vice versa; and serine (S) for threonine (T) and 
35 v1ce versa. 
of the genetic code wherein more than one codon can encode 
the same amino acid, multiple DNA sequences can code for 
the same polypeptide. Such variant DNA sequences can result 40 
from genetic drift or artificial manipulation (e.g., occurring 
during PCR amplification or as the product of deliberate 
mutagenesis of a native sequence). Deliberate mutagenesis of 
a native sequence can be carried out using numerous tech-
niques well known in the art. For example, oligonucleotide- 45 
directed site-specific mutagenesis procedures can be 
employed, particularly where it is desired to mutate a gene 
such that predetermined restriction nucleotides or codons are 
altered by substitution, deletion or insertion. Exemplary 
methods of making such alterations are disclosed by Walder 50 
eta!. (Gene 42:133,1986); Bauer eta!. (Gene 37:73, 1985); 
Craik (BioTechniques, Jan. 12-19, 1985); Smith eta!. (Ge-
netic Engineering: Principles and Methods, Plenum Press, 
1981); Kunkel (Proc. Nat!. Acad. Sci. USA 82:488,1985); 
Kunkel et a!. (Methods in Enzymol. 154.367, 1987). The 55 
present invention thus encompasses any nucleic acid capable 
of encoding a protein of the current invention. 
The current invention provides for isolated polypeptides. 
As used herein, the term "polypeptides" refers to a genus of 
polypeptide or peptide fragments that encompass the amino 60 
acid sequences identified herein, as well as smaller frag-
ments. Alternatively, a polypeptide may be defined in terms of 
its antigenic relatedness to any peptide encoded by the nucleic 
acid sequences of the invention. Thus, in one embodiment, a 
polypeptide within the scope of the invention is defined as an 65 
amino acid sequence comprising a linear or 3-dimensional 
epitope shared with any peptide encoded by the nucleic acid 
The above-mentioned substitutions are not the only amino 
acid substitutions that can be considered "conservative." 
Other substitutions can also be considered conservative, 
depending on the environment of the particular amino acid. 
For example, glycine (G) and alanine (A) can frequently be 
interchangeable, as can be alanine and valine (V). Methionine 
(M), which is relatively hydrophobic, can frequently be inter-
changed with leucine and isoleucine, and sometimes with 
valine. Lysine (K) and arginine (R) are frequently inter-
changeable in locations in which the significant feature of the 
amino acid residue is its charge and the differing pK's of these 
two amino acid residues are not significant. Still other 
changes can be considered "conservative" in particular envi-
ronments. 
The effects of such substitutions can be calculated using 
substitution score matrices such PAM120, PAM-200, and 
PAM-250 as discussed in Altschul, (J. Mol. Bioi. 219:55565 
(1991)). Other such conservative substitutions, for example, 
substitutions of entire regions having similar hydrophobicity 
characteristics, are well known. 
Naturally -occurring peptide variants are also encompassed 
by the invention. Examples of such variants are proteins that 
result from alternate mRNA splicing events or from pro-
teolytic cleavage of the polypeptides described herein. Varia-
tions attributable to proteolysis include, for example, differ-
ences in the N- or C-termini upon expression in different 
types of host cells, due to proteolytic removal of one or more 
terminal amino acids from the polypeptides encoded by the 
sequences of the invention. 
Variants of the valencene synthase of the invention may be 
used to attain desired enhanced or reduced enzymatic activity, 
modified regiochemistry or stereochemistry, or altered sub-
US 7,442,785 B2 
9 
strate utilization or product distribution. A variant or site 
direct mutant may be made by any methods known in the art. 
Variants and derivatives of native polypeptides can be 
obtained by isolating naturally-occurring variants, or the 
nucleotide sequence of variants, of other or same plant lines 
or species, or by artificially programming mutations of nucle-
otide sequences coding for native citrus polypeptides. 
10 
sense RNA. The expression of antisense RNA can be used to 
down-modulate the expression of the protein encoded by the 
mRNA to which the antisense RNA is complementary. 
A further embodiment of the invention is methods of mak-
ing terpenoids and sesquiterpene compounds, for example, 
using the nucleotides and polypeptides of the invention. 
As used herein an acyclic pyrophosphate terpene precursor 
In one embodiment, the invention contemplates: vectors 
comprising the nucleic acids of the invention. A vector as 
used herein includes any recombinant vector including but 10 
not limited to viral vectors, bacteriophages and plasmids. 
is any acyclic pryrophosphate compound that is a precursor to 
the production of at least one terpene including but not limited 
to geranyl-pyrophosphate (GPP), farnesyl-diphosphate 
(FPP) and geranylgeranyl-pyrophosphate (GGPP). 
Expression vectors containing a nucleic acid sequence of 
the invention can be prepared using well known methods and 
include a eDNA sequence encoding the polypeptide operably 
linked to suitable transcriptional or translational regulatory 15 
nucleotide sequences. Examples of regulatory sequences 
include transcriptional promoters, operators, or enhancers, 
mRNA ribosomal binding sites, and appropriate sequences 
which control transcription and translation initiation and ter-
mination. Nucleotide sequences are "operably linked" when 20 
the regulatory sequence functionally relates to the eDNA 
sequence of the invention. Expression vectors, regulatory 
elements and the construction thereof are well known in the 
In one embodiment, the distribution of products or the 
actual products formed may be altered by varying the pH at 
which the synthase contacts the acyclic pyrophosphate ter-
pene precursor. 
Also within the practice of the invention is an organism 
(e.g., microorganism or plant) that is used to construct a 
platform for high level production of a substrate of sesquit-
erpene synthases (e.g., FPP) and the introduction of a nucleic 
acid of the invention into the organism. 
Unless otherwise indicated, nucleic acids of the invention 
that are DNA encompass both eDNA (DNA reverse tran-
scribed from mRNA and lacking introns) and isolated 
genomic DNA (DNA that can contain introns.) art, and therefore are not limited to those recited above. 
In one embodiment, the nucleic acids of the invention are 
used to create other nucleic acids coding for sesquiterpene 
synthases. For example, the invention provides for a method 
of identifYing a sesquiterpene synthases comprising con-
structing a DNA library using the nucleic acids of the inven-
In addition, sequences encoding appropriate signal pep- 25 
tides that are not naturally associated with the polypeptides of 
the invention can be incorporated into expression vectors. For 
example, a DNA sequence for a signal peptide (secretory) 
leader can be fused in-frame to a nucleotide sequence of the 
invention so that the polypeptide of the invention is initially 
translated as a fusion protein comprising the signal peptide. A 
signal peptide that is functional in the intended host cells 
enhances extracellular secretion of the expressed polypep-
tide. The signal peptide can be cleaved from the polypeptide 
upon secretion from the cell. In some cases, signal peptides 
are cleaved in two or more stages; this is also within the scope 
30 tion, screening the library for nucleic acids which encode for 
at least one sesquiterpene synthase. The DNA library using 
the nucleic acids of the invention may be constructed by any 
process known in the art where DNA sequences are created 
using the nucleic acids of the invention as a starting point, 
35 including but not limited to DNA suffling. In such a method, 
the library may be screened for sesquiterpene synthases using 
a functional assay to find a target nucleic acid that encodes a 
sesquiterpene synthase. The activity of a sesquiterpene syn-
thase may be analyzed using, for example, the methods 
of the invention where appropriate. 
Fusions of additional peptide sequences at the amino and 
carboxyl terminal ends of the polypeptides of the invention 
can be used with the current invention. 
In one embodiment, the invention includes a host cell com-
prising a nucleic acid of the invention. Another embodiment 
of the invention is a method of making a recombinant host cell 
comprising introducing the vectors of the invention, into a 
host cell. In a further embodiment, a method of producing a 
polypeptide comprising culturing the host cells of the inven-
tion under conditions to produce the polypeptide is contem-
plated. In one embodiment the polypeptide is recovered. The 
methods of the invention include methods of making at least 
one valencene synthase of the invention comprising culturing 
a host cell comprising a nucleic acid of the invention, and 
recovering the sesquiterpene synthase accumulated. 
Suitable host cells for expression of polypeptides of the 
invention are well known in the art, and include, but are not 
limited to, prokaryotes, yeast, higher eukaryotic cells, or 
combinations thereof. (See for example, Pauwels eta!. Clon-
ing Vectors: A Laboratory Manual, Elsevier, New York 
(1985)). Cell-free translation systems, also well known in the 
art, could also be employed to produce the disclosed polypep-
tides using RNAs derived from DNA constructs disclosed 
herein. 
Host cells may be modified by any methods known in the 
art for gene transfer including, for example, the use of deliv-
ery devices such as lipids and viral vectors, naked DNA, 
electroporation and particle-mediated gene transfer. 
In one embodiment, the cDNAs of the invention may be 
expressed in such a way as to produce either sense or anti-
40 described herein. In one embodiment, high through put 
screening is utilized to analyze the activity of the encoded 
polypeptides. 
As used herein a "nucleotide probe" is defined as an oli-
gonucleotide or polynucleotide capable of binding to a target 
45 nucleic acid of complementary sequence through one or more 
types of chemical bonds, through complementary base pair-
ing, or through hydrogen bond formation. 
A "target nucleic acid" herein refers to a nucleic acid to 
which the nucleotide probe or molecule can specifically 
50 hybridize. The probe is designed to determine the presence or 
absence of the target nucleic acid, and the amount of target 
nucleic acid. The target nucleic acid has a sequence that is 
significantly complementary to the nucleic acid sequence of 
the corresponding probe directed to the target so that the 
55 probe and the target nucleic acid can hybridize. Preferably, 
the hybridization conditions are such that hybridization of the 
probe is specific for the target nucleic acid. As recognized by 
one of skill in the art, the probe may also contain additional 
nucleic acids or other moieties, such as labels, which may not 
60 specifically hybridize to the target. The term target nucleic 
acid may refer to the specific nucleotide sequence of a larger 
nucleic acid to which the probe is directed or to the overall 
sequence (e.g., gene or mRNA). One skilled in the art will 
65 
recognize the full utility under various conditions. 
Other than in the operating example, or where otherwise 
indicated, all numbers expressing quantities of ingredients, 
reaction conditions, and so forth used in the specification and 
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claims are to be understood as being modified in all instances 
by the term "about." Accordingly, unless indicated to the 
contrary, the numerical parameters set forth in the specifica-
tion and claims are approximations that may vary depending 
upon the desired properties sought to be obtained by the 
present invention. At the very least, and not as an attempt to 
limit the application of the doctrine of equivalents to the scope 
of the claims, each numerical parameter should be construed 
in light of the number of significant digits and ordinary round-
ing approaches. 
Notwithstanding that the numerical ranges and parameters 
setting forth the broad scope of the invention are approxima-
tions, the numerical values set forth in the specific examples 
are reported as precisely as possible. Any numerical value; 
however, inherently contains certain errors necessarily result-
ing from the standard deviation found in their respective 
testing measurements. 
Hundreds of genes with similarity to terpene synthases are 
readily observed in protein sequence or keyword searches of 
GenBank with a significant percentage of these currently 
annotated as terpene synthase-like. In order to isolate syn-
thase genes coding for enzymes that share catalytic features 
in common with tobacco 5-epi-aristolochene synthase 
(TEAS) or Hyoscyamus muticus prenmaspirodiene synthase 
(HPS) (FIG. 1), Inventors considered possible biosynthetic 
routes for all isomeric forms of the eremophilane-type ses-
quiterpenes (FIG. 2). ( + )Valencene and its oxygenated 
derivative nootkatone (FIG. 3) were readily recognized as 
high value natural products isolated from citrus used as flavor 
enhancers. To identifY the terpene synthase responsible for 
the biosynthesis ofvalencene, Inventors screened sequences 
from several citrus (Citrus x paradisi and Citrus junos) EST 
sequencing projects deposited in GenBank (www.ncbi.nlm-
.nih.gov/Genbank/index.html) for sequences similar to 
TEAS and HPS. Two sequences were observed, one from 
Citrus junos ( accessionAF288465) and the other from Citrus 
paradisi (accessionAF411120). The predicted proteins from 
both of these cDNAs were between about 40% identical and 
about 60% similar to TEAS, but the C. junos eDNA predicted 
a protein that was missing segments of 10 and 12 amino acids 
relative to TEAS. The isolated protein from Citrus paradisi 
was 45% homologous with TEAS (see below). Inventors, 
therefore, focused on the isolation and characterization of a 
full-length eDNA corresponding to AF411120 from grape-
fruit (C. paradisi). 
The eDNA isolated by Inventors is a terpene synthase gene, 
the protein product of which is citrus valencene synthase 
(CVS). The following non-limiting examples describe Inven-
tors isolation, and expression of the CVS gene, and also 
further characterize the CVS protein via enzyme activity 
assays and pH assays. Applicants have further characterized 
the key amino acid residues comprising the active domain of 
the CVS protein via these enzyme activity assays and via a 
comparison to other eremophilane-type sesquiterpenes, in 
particular TEAS, HPS and delta-cadinene synthase from cot-
ton. 
Sequence comparisons between terpene synthases have 
suggested that simple sequence alignments are not sufficient 
to identifY amino acids or protein regions contributing to 
catalytic specificity. Inventors aligned the residues forming 
the active region of the isolated CVS with the residues form-
ing active region of TEAS. In order to perform a comparative 
analysis of the two active regions (CVS and TEAS), the 
absolute amino acid number for CVS was shifted to corre-
spond with the TEAS amino acid numbers. FIG.16 illustrates 
the alignment of CVS amino acid residues with those of 
TEAS and maintains the numbering of TEAS and the num-
12 
bering for CVS. Inventors then adjusted the amino acid num-
bering of CVS to match that of TEAS (comparative number-
ing). Tier 1 and Tier 2 amino acid numbering follows this 
comparative numbering, thus, Tier 1 and Tier 2 amino acids 
would also have the comparative numbering shift (SEQ ID 
NOS.: 7 and 8, respectively). FIG.17. Thus, as is used herein 
the term "absolute numbering" refers to the sequence number 
of the CVS amino acid residues in SEQ ID NO.: 1 and the 
nucleotide numbering in SEQ ID NO.: 4. As used herein, the 
10 term "comparative numbering" refers to the sequence num-
bering of the amino acid residues based on the TEAS num-
bering, which were designated as a means to compare TEAS 
and CVS active site amino acid residues, and neighboring 
residues (Tiers 1 and 2). Nucleic acid residues coding for the 
15 amino acids comprising Tier 1 (SEQ ID NO.: 5) and Tier 2 
(SEQ ID NO.: 6) are based on the nucleotide sequence of SEQ 
ID NO.: 1, and are absolute numbers. 
As is seen in FIG. 4 and FIG. 11 wherein Inventors com-
pared the amino acids of TEAS, HPS and CVS, only a single 
20 amino acid difference was observed within the 1st tier resi-
dues of TEAS and CVS; however 8 amino acid differences 
were observed within the second tier residues of TEAS and 
CVS. CVS exhibits an alanine at position 403 rather than a 
threonine as is found in TEAS. Using this discovery, Inven-
25 tors have further compared amino acid residues surrounding 
the active site and discovered that these amino acids, termed 
Tier 2 amino acids and discussed below, influence the cata-
lytic outcome of these enzymes. 
For clarity in this disclosure, Tier 1 amino acids are the 
30 amino acid residues that form the catalytic pocket in a ses-
quiterpene synthase, and Tier 2 amino acids are those amino 
acids that are within a few angstroms of the Tier 1 residues, 
preferably between the range of about 1 angstrom and about 
5 angstroms, more preferably between the range of about 2 
35 angstrom and about 4 angstrom and most preferably 3 ang-
strom. In this disclosure, the amino acid residue sequence for 
Tier 1 and Tier 2, based on the amino acid residue sequence of 
SEQ ID NO.: 4, but adjusted for a comparative analysis with 
TEAS, are SEQ ID NO.: 7, shown in FIG. 14b, and SEQ ID 
40 NO.: 8, shown in FIG. 15b. The corresponding nucleotide 
sequence for the Tier 1 and Tier 2 amino acid residues, there-
fore, are based on the nucleotide sequence of SEQ ID NO.: 1, 
and are SEQ ID NO.: 5, shown in FIG. 12, and SEQ ID NO.: 
6, shown in FIG. 13. The recited amino acid residue 
45 sequences, recited position number, corresponding nucle-
otide and nucleotide position number are based on the full 
protein and nucleotide sequences recited in SEQ ID N0.1 and 
SEQ ID NO.: 4, respectively. Because the current invention 
accounts for frame shift mutations, fusion proteins, frag-
50 ments, degeneracy of the genetic code and other events that 
can change these recited sequences and positions without 
loosing the spirit of the current invention, the sequences and 
positions of these events are included in the current invention. 
Inventors then analyzed the second tier amino acid residues 
55 for the TEAS and CVS protein sequences. Second tier resi-
dues, those amino acid R groups within a few A of the 1st tier 
amino acids, were examined for differences between TEAS 
and CVS (FIG. 4). Three positions within the 2nd tier exhib-
ited common differences between TEAS and CVS (positions 
60 402, 436 and 516), as well as substitutions unique to CVS 
(270, 401,407,448, 515) relative to TEAS. A role for 2nd tier 
residues in catalysis, then, includes determining whether a 
synthase produces a C7 -C8 double bond or a C6-C7 double 
bond. This arises because the final proton abstraction 
65 occurred at C6 rather than C8, a spatial distance of 3-4 A or 
approximately the diameter of a methyl group. Equally 
important, regia-specific abstraction necessarily arises from 
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proper geometric positioning ofC8 orC6 of the eremophylyl 
cation in proximity to an active site residue or activated water 
molecule capable of the final abstraction. Positioning of the 
final reaction intermediate therefore comes about by simple 
spatial allowances created by the presence or absence of 
slightly bulkier R -groups on one side of the active site pocket 
balanced by the converse on the opposite site of the pocket. 
For instance, the poly-threonine sequence at positions 401-
403 of TEAS is replaced by the small amino acids serine, 
cysteine and alanine in CVS, which appear balanced by a 10 
smaller amino acid (valine 516) on the opposite side of the 
active site pocket in TEAS and the larger amino acid isoleu-
cine in CVS. Without being bound by any theory, differences 
between sesquiterpene synthases, particularly TEAS and 
CVS may be due to alterations of the active site architecture 15 
affecting the proton donor positioning for proton donation; 
and/or a dynamic mechanism wherein the intermediate com-
pounds are brought into proper stereoelectronic alignment for 
the proton donation and cyclization geometry. 
14 
Yet another aspect of the invention is an isolated nucleic 
acid that hybridizes to the nucleic acid of SEQ ID NO: 1 under 
stringent conditions with no more than about a 5% mismatch. 
Preferably, there is no more than about a 2% mismatch. More 
preferably, there is no more than about a 1% mismatch. Typi-
cally, the nucleic acid is DNA. 
Yet another aspect of the invention is an isolated nucleic 
acid that encodes a protein that is at least 500 amino acids in 
length, that specifically binds farnesyl pyrophosphate in a 
hydrophobic pocket, and that has sesquiterpene synthase 
activity, wherein the nucleic acid includes SEQ ID NO.5 and 
SEQ ID NO. 6. Typically, the nucleic acid is DNA. 
Still another aspect of the invention is an isolated nucleic 
acid that encodes a protein that is at least 500 amino acids in 
length, that specifically binds farnesyl pyrophosphate in a 
hydrophobic pocket, and that has sesquiterpene synthase 
activity, wherein the nucleic acid includes SEQ ID NO. 5. 
Typically, the nucleic acid is DNA. 
Still another aspect of the invention is an isolated nucleic 
There now follows a description of the isolation, cloning, 
sequencing and functional characterization of citrus valen-
cene synthase from Citrus paradisi. These examples are pro-
vided for the purpose of illustrating the invention, and are not 
to be considered as limiting. 
20 acid that encodes a protein that includes amino acid residues 
264 to 528 of SEQ ID NO.4, wherein the protein specifically 
binds farnesyl pyrophosphate in a hydrophobic pocket and 
has sesquiterpene synthase activity. Typically, the nucleic 
acid is DNA. 
Accordingly, one aspect of the present invention is an iso- 25 
lated nucleic acid comprising the nucleic acid sequence of 
SEQ ID NO 1. The nucleic acid is typically DNA, but can be 
RNA. If it is DNA, it is typically double-stranded, but can 
alternatively be single-stranded. Alternatively, it can be an 
RNA-DNA hybrid, i.e., either a complete or partial hybrid. 30 
Another aspect of the present invention is an isolated 
nucleic acid that encodes the amino acid sequence of SEQ ID 
NO: 4. The nucleic acid is typically DNA, but can be RNA. If 
it is DNA, it is typically double-stranded, but can alternatively 
35 
be single-stranded. Alternatively, it can be an RNA-DNA 
hybrid, i.e., either a complete or partial hybrid. 
Another aspect of the present invention is an isolated 
nucleic acid encoding a protein that has the amino acid 
sequence of SEQ ID NO. 4 with 0 to 20 conservative amino 40 
acid substitutions, with the proviso that a conservative amino 
acid substitution is not made at amino acids 264, 273, 403, 
404, 440, 444, 520, 527, and 528 in the protein that has the 
amino acid sequence of SEQ ID NO: 4, wherein the encoded 
protein specifically binds farnesyl pyrophosphate in a sub- 45 
stantially hydrophobic pocket and has sesquiterpene synthase 
activity. Conservative amino acid substitutions are defined as 
above. Preferably, the nucleic acid sequence encodes a pro-
tein with 0 to 10 conservative amino acid substitutions. More 
preferably, the nucleic acid sequence encodes a protein with 50 
0 to 5 conservative amino acid substitutions. Typically, the 
nucleic acid is DNA. 
Yet another aspect of the present invention is an isolated 
nucleic acid encoding a protein that has the amino acid 
sequence of SEQ ID NO. 4 with 0 to 20 conservative amino 55 
acid substitutions, with the proviso that a conservative amino 
acid substitution is not made at amino acids 20, 264, 266, 270, 
273,298,302,372,376,401,402,403,404,407,436,440, 
441,444,445,448,512,515,516,519,520,527,528,and529 
in the protein that has the amino acid sequence of SEQ ID 60 
NO: 4, wherein the encoded protein specifically binds farne-
syl pyrophosphate in a substantially hydrophobic pocket and 
has sesquiterpene synthase activity. Preferably, the nucleic 
acid sequence encodes a protein with 0 to 10 conservative 
amino acid substitutions. More preferably, the nucleic acid 65 
sequence encodes a protein with 0 to 5 conservative amino 
acid substitutions. Typically, the nucleic acid is DNA. 
As defined above, another embodiment of the invention is 
an isolated polypeptide having appropriate enzymatic activ-
ity, namely sesquiterpene synthase activity. These isolated 
polypeptides include, but are not necessary limited to: 
(1) the polypeptide of SEQ ID NO: 4; 
(2) a polypeptide that has the amino acid sequence of SEQ 
ID NO.4 with 0 to 20 conservative amino acid substi-
tutions, with the proviso that a conservative amino acid 
substitution is not made at amino acids 264, 273, 403, 
404, 440, 444, 520, 527, and 528 in the protein that has 
the amino acid sequence of SEQ ID NO: 4, wherein the 
encoded protein specifically binds farnesyl pyrophos-
phate in a substantially hydrophobic pocket and has 
sesquiterpene synthase activity, preferably with 0 to 10 
conservative amino acid substitutions, more preferably 
with 0 to 5 conservative amino acid substitutions; 
(3) a polypeptide that has the amino acid sequence of SEQ 
ID NO.4 with 0 to 20 conservative amino acid substi-
tutions, with the proviso that a conservative amino acid 
substitution is not made at amino acids 20, 264, 266, 
270,273,298,302,372,376,401,402,403,404,407, 
436,440,441,444,445,448,512,515,516,519,520, 
527, 528, and 529 in the protein that has the amino acid 
sequence of SEQ ID NO: 4, wherein the encoded protein 
specifically binds farnesyl pyrophosphate in a substan-
tially hydrophobic pocket and has sesquiterpene syn-
thase activity, preferably with 0 to 10 conservative 
amino acid substitutions, more preferably with 0 to 5 
conservative amino acid substitutions; 
( 4) a polypeptide encoded by an isolated nucleic acid that 
hybridizes to the nucleic acid of SEQ ID NO: 1 under 
stringent conditions with no more than about a 5% mis-
match, preferably no more than about a 2% mismatch, 
more preferably no more than about a 1% mismatch; 
( 5) a polypeptide that is at least 500 amino acids in length, 
that specifically binds farnesyl pyrophosphate in a 
hydrophobic pocket, and that has sesquiterpene syn-
thase activity, wherein the sequence of the protein 
includes SEQ ID NO. 7 and SEQ ID NO. 8; 
( 6) a polypeptide that is at least 500 amino acids in length, 
that specifically binds farnesyl pyrophosphate in a 
hydrophobic pocket, and that has sesquiterpene syn-
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thase actlv1ty, wherein the sequence of the protein 
includes SEQ ID NO. 7; and 
16 
(7) a polypeptide that includes amino acid residues 264 to 
528 of SEQ ID NO. 4, wherein the protein specifically 
binds farnesyl pyrophosphate in a hydrophobic pocket 5 
and has sesquiterpene synthase activity. 
Goedde! eta!., Nature 281:544, 1979), tryptophan (trp) pro-
moter system (Goedde! eta!., Nucl. Acids Res. 8:4057, 19 .80; 
and EP-A-36776), and tac promoter (Maniatis, MoLecular 
Cloning: A Laboratory Manual, Cold Spring Harbor Labora-
tory, p. 412. 1982). A particularly useful prokaryotic host cell 
expression system employs a phage A PL promoter and a 
Typically, the sesquiterpene synthase activity of proteins or 
polypeptides within the scope of the present invention is 
valencene synthase activity, but other sesquiterpenes can be 
synthesized by proteins or polypeptides within the scope of 10 
the present invention, either as the major reaction product or 
c1857ts thermolabile repressor sequence. Plasmid vectors 
available from the American Type Culture Collection 
("ATCC"), which incorporate derivatives of the PL promoter, 
include plasmid pHUB2 (resident in E. coli strain JMB9 
(ATCC 37092)) and pPLc28 (resident in E. coli RR1 (ATCC 
in side reactions. 53082)). 
Another embodiment of the present invention is a vector 
comprising a nucleic acid of the present invention, as 
described above, operably linked to at least one control 15 
sequence. Typically, the control sequence is a promoter or 
enhancer. As described above, such vectors are well known in 
the art. 
Polypeptides of the invention can also be expressed in yeast 
host cells, preferably from the Saccharomyces genus (e.g., S. 
cerevisiae ). Other genera of yeast, such as Pichi a or 
Kluyveromyces (e.g. K. lactis), can also be employed. Yeast 
vectors will often contain an origin of replication sequence 
from a 2fl yeast plasmid, an autonomously replicating 
sequence (ARS), a promoter region, sequences for polyade-Yet another embodiment of the present invention is a host 
cell transformed or transfected with a vector of the present 
invention. The host cell can be a prokaryotic cell or a eukary-
otic cell, such as a bacterial cell, a yeast cell, a plant cell, or an 
animal cell, such as an insect cell or a mmalian cell. Typi-
cally, the host cell transformed or transfected with the vector 
is capable of expressing the protein or polypeptide encoded 
by the vector. Suitable host cells for expression of polypep-
tides of the invention include prokaryotes, yeast or higher 
eukaryotic cells. Appropriate cloning and expression vectors 
for use with bacterial, fungal, yeast, and mammalian cellular 
hosts are described, for example, in Pauwels eta!., Cloning 
Vectors. A Laboratory Manual, Elsevier, N.Y., (1985). Cell-
free translation systems could also be employed to produce 
the disclosed polypeptides using RNAs derived from DNA 
constructs disclosed herein. 
Prokaryotes include gram negative or gram positive organ-
isms, for example, E. coli or Bacilli. Suitable prokaryotic host 
cells for transformation include, for example, E. coli, Bacillus 
subtilis, Salmonella typhimurium, and various other species 
within the genera Pseudomonas, Streptomyces, and Staphy-
lococcus. In a prokaryotic host cell, such as E. coli, the 
polypeptides can include aN -terminal methionine residue to 
facilitate expression of the 16 recombinant polypeptide in the 
prokaryotic host cell. The N-terminal methionine can be 
cleaved from the expressed recombinant polypeptide. 
Examples of useful expression vectors for prokaryotic host 
cells include those derived from commercially available plas-
mids such as the cloning vector pET plasmids (Novagen, 
Madison, Wis., USA) or yet pBR322 (ATCC 37017). 
pBR322 contains genes for ampicillin and tetracycline resis-
tance and thus provides simple means for identifying trans-
formed cells. To construct an expression vector using 
pBR322, an appropriate promoter and a DNA sequence 
encoding one or more of the polypeptides of the invention are 
inserted into the pBR322 vector. Other commercially avail-
able vectors include, for example, pKK223-3 (Pharmacia 
Fine Chemicals, Uppsala, Sweden) and pGEM-1 (Promega 
Biotec, Madison, Wis., USA). Other commercially available 
vectors include those that are specifically designed for the 
expression of proteins; these would include pMAL-p2 and 
pMAL-c2 vectors that are used for the expression of proteins 
fused to maltose binding protein (New England Biolabs, Bev-
erly, Mass., USA). 
Promoter sequences commonly used for recombinant 
prokaryotic host cell expression vectors include bacterioph-
age T7 promoter (Studier F. W. and Moffatt B. A., J. Mol. 
Bioi. 189:113, 1986), ~-lactamase (penicillinase), lactose 
promoter system (Chang eta!., Nature 275:615, 1978; and 
20 nylation, sequences for transcription termination, and a 
selectable marker gene. Suitable promoter sequences for 
yeast vectors include, among others, promoters for metal-
lothionine, 3-phosphoglycerate kinase (Hitzeman et a!., J. 
Bioi. Chern. 255:2073, 1980), or other glycolytic enzymes 
25 (Hess eta!., J.Adv. Enzyme Reg. 7:149, 1968; and Hollandet 
a!., Biochem. 17:4900, 1978), such as enolase, glyceralde-
hyde phosphate dehydrogenase, hexokinase, pyruvate decar-
boxylase, phosphofructokinase, glucose phosphate 
isomerase, 3-phosphoglycerate mutase, pyruvate kinase, tri-
30 osephosphate isomerase, phosphoglucose isomerase, and 
glucokinase. Other suitable vectors and promoters for use in 
yeast expression are further described in Hitzeman, EPA-73, 
657 orinF!eeret. a!., Gene, 107:285-195 (1991); and van den 
Berg et. a!., Bio/Technology, 8:135-139 (1990). Another 
35 alternative is the glucose-repressible ADH2 promoter 
described by Russell eta!. (J. Bioi. Chern. 258:2674, 1982) 
and Beier eta!. (Nature 300:724, 1982). Shuttle vectors rep-
licable in both yeast and E. coli can be constructed by insert-
ing DNA sequences from pBR322 for selection and replica-
40 tion in E. coli (Ampr gene and origin of replication) into the 
above-described yeast vectors. 
In one embodiment, mammalian or insect host cell culture 
systems are employed to express recombinant polypeptides 
of the invention. Baculovirus systems for production ofhet-
45 erologous proteins in insect cells are reviewed by Luckow and 
Summers, BioTechnology 6:47 (1988). Established cell lines 
of mammalian origin also can be employed. Examples of 
suitable mammalian host cell lines include the COS-7 line of 
monkey kidney cells (ATCC CRL 1651) (Gluzman eta!., Cell 
50 23:175, 1981), L cells, C1 27 cells, 3T3 cells (ATCC CCL 
163), Chinese hamster ovary (CHO) cells, HeLa cells, and 
BHK (ATCC CRL 10) cell lines, and the CV-1/EBNA-1 cell 
line (ATCC CRL 10478) derived from the African green 
monkey kidney cell line CVI (ATCC CCL 70) as described by 
55 McMahan eta!. (EMBO J. 10: 2821,1991). 
In one embodiment, transfected DNA is integrated into a 
chromosome of a non-human organism such that a stable 
recombinant system results. Any chromosomal integration 
method known in the art may be used in the practice of the 
60 invention, including but not limited to, recombinase-medi-
ated cassette exchange (RMCE), viral site specific chromo-
somal insertion, adenovirus, and pronuclear injection. 
Yet another embodiment of the present invention is a non-
human multicellular organism that is modified to harbor a 
65 nucleic acid of the present invention such that the nucleic acid 
can be expressed in the non-human multicellular organism. 
The non-human multicellular organism can be, but is not 
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necessarily limited to, a plant or insect. The plant can be the 
tobacco plant. The non-human organism can be modified by 
any of the methods known in the art for gene transfer and the 
production of transgenic organisms, including, but not nec-
essarily limited to, the use of delivery devices such as lipids 
and viral vectors, naked DNA, electroporation, and particle-
mediated gene transfer. 
Established methods for introducing DNA into mamma-
lian cells have been described (Kaufinan, R. J., Large Scale 
10 
Mammalian Cell Culture, 1990, pp. 15-69). Additional pro-
tocols using commercially available reagents, such as Lipo-
fectamine (Gibco/BRL) or Lipofectamine-Plus, can be used 
to transfect cells (Feigner et a!., Proc. Nat!. Acad. Sci. USA 
84:7413-7417, 1987). In addition, electroporation can be 15 
used to transfect mammalian cells using conventional proce-
dures, such as those in Sambrook eta!. Molecular Cloning: A 
Laboratory Manual, 2 ed. Vol. 1-3, Cold Spring Harbor Labo-
ratory Press, 1989). Selection of stable transformants can be 
performed using resistance to cytotoxic drugs as a selection 20 
method. Kaufman eta!., Meth. in Enzymology 185:487-511, 
1990, describes several selection schemes, such as dihydro-
folate reductase (DHFR) resistance. A suitable host strain for 
DHFR selection can be CHO strain DX-131 1, which is 
deficient in DHFR (Urlaub and Chasin, Proc. Nat!. Acad. Sci. 25 
USA 77:4216-4220, 1980). A plasmid expressing the DHFR 
eDNA can be introduced into strain DX -131 1, and only cells 
that contain the plasmid can grow in the appropriate selective 
media. 
Transcriptional and translational control sequences for 30 
mammalian host cell expression vectors can be excised from 
viral genomes. Commonly used promoter sequences and 
enhancer sequences are derived from polyoma virus, aden-
ovirus 2, simian virus 40 (SV40), and human cytomegalovi-
rus. DNA sequences derived from the SV 40 viral genome, for 35 
example, SV 40 origin, early and later promoter, enhancer, 
splice, and polyadenylation sites can be used to provide other 
genetic elements for expression of a structural gene sequence 
in a mammalian host cell. Viral early and late promoters are 
particularly useful because both are easily obtained from a 40 
viral genome as a fragment, which can also contain a viral 
origin of replication (Piers eta!., Nature 273:113, 1978; Kau-
finan, Meth. in Enzymology, 1990). 
There are several methods known in the art for the creation 
45 
of transgenic plants. These include, but are not limited to: 
electroporation of plant protoplasts, liposome-mediated 
transformation, polyethylene-glycol-mediated transforma-
tion, microinjection of plant cells, and transformation using 
viruses. In one embodiment, direct gene transfer by particle 
50 
bombardment is utilized. 
Direct gene transfer by particle bombardment provides an 
example for transforming plant tissue. In this technique a 
particle, or microprojectile, coated with DNA is shot through 
the physical barriers of the cell. Particle bombardment can be 55 
used to introduce DNA into any target tissue that is penetrable 
by DNA coated particles, but for stable transformation, it is 
imperative that regenerable cells be used. Typically, the par-
ticles are made of gold or tungsten. The particles are coated 
with DNA using either CaCI2 or ethanol precipitation meth- 60 
ods which are commonly known in the art. 
DNA coated particles are shot out of a particle gun. A 
suitable particle gun can be purchased from Bio-Rad Labo-
ratories (Hercules, Calif.). Particle penetration is controlled 
by varying parameters such as the intensity of the explosive 65 
burst, the size of the particles, or the distance particles must 
travel to reach the target tissue. 
18 
The DNA used for coating the particles may comprise an 
expression cassette suitable for driving the expression of the 
gene of interest that will comprise a promoter operably linked 
to the gene of interest. 
Methods for performing direct gene transfer by particle 
bombardment are disclosed in U.S. Pat. No. 5,990,387 to 
Tomes et a!., incorporated herein by this reference. 
In one embodiment, the cDNAs of the invention may be 
expressed in such a way as to produce either sense or anti-
sense RNA. Antisense RNA is RNA that has a sequence 
which is the reverse complement of the mRNA (sense RNA) 
encoded by a gene. A vector that will drive the expression of 
antisense RNA is one in which the ONA is placed in "reverse 
orientation" with respect to the promoter such that the non-
coding strand (rather than the coding strand) is transcribed. 
The expression of antisense RNA can be used to down-modu-
late the expression of the protein encoded by the mRNA to 
which the antisense RNA is complementary. Vectors produc-
ing antisense RNAs could be used to make transgenic plants, 
as described above. 
In one embodiment, transfected DNA is integrated into a 
chromosome of a non-human organism such that a stable 
recombinant systems results. Any chromosomal integration 
method known in the art may be used in the practice of the 
invention, including but not limited to, recombinase-medi-
ated cassette exchange (RMCE), viral site specific chromo-
somal insertion, adenovirus, and pronuclear injection. 
Still another embodiment of the invention is a method of 
producing a sesquiterpene synthase comprising the steps of: 
(1) culturing a host cell transformed or transfected by a 
vector of the present invention under conditions in 
which the sesquiterpene synthase encoded by the vector 
is expressed; and 
(2) isolating the sesquiterpene synthase expressed by the 
host cell. 
Typically, the sesquiterpene synthase is valencene syn-
thase, as described above. 
Yet another embodiment of the invention is a method of 
producing a sesquiterpene comprising the steps of: 
(1) reacting a protein or polypeptide of the present inven-
tion having sesquiterpene synthase enzymatic activity 
with farnesyl pyrophosphate under conditions in which 
the enzymatic activity catalyzes the formation of a ses-
quiterpene; and 
(2) isolating the sesquiterpene formed in step (1). 
Typically, the sesquiterpene synthase is a valencene syn-
thase, in which case the sesquiterpene formed is valencene. 
Still another embodiment of the present invention is a 
method of producing nootkatone. In one alternative of this 
embodiment, the method comprises the steps of: 
(1) reacting a protein or polypeptide of the present inven-
tion having valencene synthase enzymatic activity with 
farnesyl pyrophosphate under conditions in which the 
enzymatic activity catalyzes the formation of valencene; 
(2) reacting the valencene formed in step (1) by regia-
specific hydroxylation and then oxidation to form noot-
katone; and 
(3) isolating the nootkatone produced. 
The second step could be catalyzed by a single multifunc-
tional hydroxylase or could be catalyzed by sequential 
enzyme mediated reactions. 
Yet another embodiment of the invention is an antisense 
nucleic acid that is the complement of a nucleic acid accord-
ing to the present invention as described above. 
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EXAMPLES 
A eDNA of 1710 bp was prepared from fresh grapefruit via 
RT-PCR using non-degenerate primers designed to amplify 
from the translation start to stop sites of AF411120, then 5 
inserted into appropriate vectors for DNA sequencing and 
bacterial expression. For enzymological studies, the eDNA 
was inserted into a pET expression vector in-frame with an 
amino terminal hexa-histidine tag, and lysates of appropri-
ately grown bacterial cultures used for nickel-affinity purifi- 10 
cation of the citrus eDNA encoded protein. The isolated citrus 
protein was approximately 30-40% pure as determined by 
Coomassie blue staining after SDS-PAGE and migrated as a 
64 kD polypeptide (data not shown). The conceptual transla-
tion of the isolated eDNA predicted a protein of 548 amino 15 
acids having a molecular size of 63,646 daltons. 
Example 1 
20 
plasmid as template under standard PCR conditions. The 
PCR product was digested with EcoRI and Xhoi, purified 
using a QIAquick PCR purification kit (Qiagen, Valencia, 
Calif.), and ligated into a pET-28a( +) expression vector 
(Novagen, San Diego, Calif.) that had been digested with 
corresponding enzymes (NEB, Beverly Mass.), dephospho-
rylated with calf intestine alkaline phosphatase (Invitrogen, 
Carlsbad, Calif.), and purified with a QIAquick kit. Proper 
construction of the resulting expression vector was verified 
by DNA sequencing and subsequently referred to as the pET-
28a( + )-CVS expression vector. The expression vector was 
transformed into BL21 (DE3) cells (Stratagene, La Jolla, 
Calif.), and grown in a 10 mL inoculate ofLB Growth Media, 
using well known techniques. The cells were grown to an 
OD600=1. IPTG (Sigma-Aldrich, St. Louis, Mo.) was used to 
induce expression of the putative valencene synthase gene. 
The transformed cells were incubated at 28° C. for four hours, 
centrifuged to form a pellet and the pellet was collected and 
Molecular Cloning of a Citrus Sesquiterpene 
Synthase eDNA 
20 resuspended in 1 mL of cyclase buffer (200 mM Tris-HCl, pH 
7.5, 40 mM MgC12). Cells were then sonicated with three 
1 O-see bursts using a microtip ultrasonicator at 40% power 
and the lysate was centrifuged at 1 O,OOOxg for 10 minutes. RNA was isolated from the juice vesicles of freshly har-
vested red grapefruit using TRIZOL reagent and following 
the manufacturer's protocol (Invitrogen Corp., Carlsbad, 25 
Calif.). Reverse transcription of the isolated RNA also fol-
lowed manufacturer's protocol, and 10 flg of total RNA was 
reverse transcribed using Superscript II RNase H (Stratagene, 
La Jolla Calif.) and a reverse primer ( 18 nucleotides in length) 
complementary to the 3' end including the stop codon of the 30 
AF411120 sequence reported in Genbank. A full-length 
eDNA was then amplified using Pfu turbo Taq polymerase 
(Stratagene, La Jolla Calif.), more of the initial reverse 
primer, a forward primer (18 nucleotides in length) comple-
mentary to the 5' end initiating at the start codon, and an 35 
aliquot of the first strand eDNA using standard PCR condi-
tions. An amplification fragment approximating the expected 
size of 1,800 bp was observed by agarose gel electrophoresis, 
T/A cloned into the pgem T-easy vector (Promega, Madison, 
Wis.) and then subjected to automated DNA sequencing 40 
using the BigDye terminator system with an ABI 310 
sequencer. The sequence, which is shown in FIG. 5, was 
obtained from start to stop codons in duplicate and rectified 
with the reported sequence for the Citrus x paradisi putative 
terpene synthase mRNA. (Seq ID: 1 ). One nucleotide was 45 
found to be altered in the recovered eDNA, 1544 bp 5' to the 
ATG start site an A instead of a G was observed, converting 
codon 492 from specifYing an aspartate to an arginine. 
Sequence analysis was performed using software tools avail-
able from the NCBI web site (www.ncbi.nlm.nih.gov) or 50 
using ClustalX. 
Example 2 
Expression of Citrus Valencene Synthase in E. coli 55 
Samples of the lysate were divided and some samples were 
assayed for protein purity, while other samples were used in 
Example 3 below. For the protein purity assay, protein was 
purified by nickel affinity chromatography according to 
Mathis eta!. (J. R. Mathis, K. Back, C. Starks, J. Noel, C. D. 
Poulter, J. Chappell, Biochem. 36 (1997) 8340-8348). Iso-
lated CVS protein was approximately 30 to 40% pure based 
on the intensity of Coomassie blue staining of samples ana-
lyzed by SDS-PAGE. A protein sequencing reaction was per-
formed via the Edman Degradation reaction performed using 
a Perkin Elmer Applied Biosystems Model 494 Procise pro-
tein/peptide sequencer with an on-line Perkin Elmer Applied 
Biosystems Model 140C PTH Amino Acid Analyzer. The 
protein sequence for the expressed CVS protein is shown in 
FIG. 6. (SEQ ID NO.; 4) 
Partially purified protein was subsequently incubated with 
FPP at pH 7.5 using typical sesquiterpene synthase reaction 
conditions and the pentane extractable products examined by 
GC-MS (FIG. 7). Two compounds accounting for greater 
than 95% of the total reaction products dominated the GC 
profiles and were identified as beta-elemene (30%) and valen-
cene (65%) on the basis ofMS matches with authentic stan-
dards. The beta-elemene peak most certainly represents a 
thermal rearrangement product of germacrene A resulting 
from high temperature injection into the GC. 
Example 3 
Terpene Synthase Activity Assays and Reaction 
Product Identification 
Small scale reactions of 50 f.LL were used for screening 
purposes and rate determinations. Reactions typically con-
tained 200 mM Tris-HCl, pH 7.5, 40 mM MgC12 , 0.5 fJ.Ci 
[1-3H]FPP, 25-30 f.LM FPP and 160 nM enzyme. For kinetic 
The Citrus valencene synthase (CVS) eDNA was inserted 
into an appropriate expression vector, pGEM to provide an 
amino-terminal hexa-histidyl tag for protein purification after 
expression of the putative valencene synthase eDNA in E. 
coli. The eDNA was re-amplified using PCR primers 
designed to amplify from the ATG start codon (5'-GGG-
GAATTCATCTGGTCTGGAGAAACATTTCGTCC-3' 
(SEQ ID NO.: 2) to the TGA stop codon (5'-CCGCTCGAG-
GAAGTATAGAACTAGTCGTCAAAATGG-3' (SEQ ID 
N0.:3)) and to provide restriction sites EcoRI and Xhoi, 
(NEB, Beverly Mass.) respectively, using the pGEM-CVS 
60 determinations, 10 f.LL aliquots ofFPP (giving final concen-
trations of 0.7-23 f.LM) were rapidly mixed with 40 f.LL of 
enzyme solution at room temperature (23 o C.) and allowed to 
incubate for 1 minute. The reactions were terminated by 
addition of 150 f.LL of a 100 mM KOH, 0.5 M EDTA stop 
65 solution. Reactions were extracted with 500 f.LL ofhexane and 
an aliquot was taken for determination of radio labeled hydro-
phobic product via liquid scintillation counting. Hexane 
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extracted samples were not subject to silica chromatography 
prior to counting because background was minimal and syn-
thase mutants could possibly produce reaction products con-
taining alcohols, which would bind to silica. Kinetic con-
stants were determined from direct fits of the Michaelis-
Menton equation to the data using Graphpad Prism 2.01 
software. 
22 
30 mx0.25 mm i.d.x0.25 m thickness with He as the carrier 
gas at 2 mL/min and a temperature gradient of 10° C./min 
from 50° C. (5-min hold) to 180° C. (4-min hold). GC/MS 
data was analyzed using HP-Chemstation software (version 
B.01.00) and integration of terpene peaks used for quantifi-
cation. 
Initial synthase reaction products were examined by GC-
MS. Preparative reactions were performed similarly to the 
reactions described above except they were scaled to 2.5 mL 10 
and employed 2 f.LM of purified enzyme and 80 f.LM of unla-
beled FPP. The reactions were incubated for 1 hr and then 
As seen in FIG. 10, a pH dependent transition between 
valencene and germacrene A biosynthesis occurs at approxi-
mately pH 8.2. Inventors interpreted this as a titration point 
for the protonation of germacreneA. This pH value is close to 
the pKa value of8.3-8.5 for free cysteine, which is involved in 
the second protonation step of the chemical cascade catalyzed 
by TEAS. Those results demonstrated that when C440 of 
extracted twice with 2 mL of pentane. Pooled extracts were 
dried to 50 f.LL under a stream of nitrogen gas and 1 f.LL aliquots 
15 TEAS was mutated to alanine, a robust germacrene A syn-
thetic activity resulted. In combination with the sequence data 
provided in SEQ ID NO.: 7 and SEQ ID NO.: 8, it is apparent 
that germacrene synthases consistently differ from CVS, 
of this organic extract were analyzed by GC-MS using an 
HP-GCDplus (Hewlett-Packard, Palo Alto, Calif.) equipped 
with a DB-5 ms column, an injector temperature of 250° C. 
and the mass selective detector set to scan for ions within the 
range from 45 to 250 m/z. The GC was programmed to hold 20 TEAS and HPS by the absence of cysteine at position 440 in 
their putative active site while Y520, previously implicated in 
the same protonation step, is conserved. The observation of 
germacrene A as a reaction product and the pH dependence 
for its synthesis are consistent with its intermediacy in the 
for 1 minute at 100° C., followed by a temperature ramp of 8° 
C./min to a final temperature of270° C. The results are shown 
in FIG. 7. Spectra from this analysis was compared to the 
NIST library standard for beta-elemene (FIG. 8) and to that 
25 
for a sample of valencene purchased from Fluka Chemical reaction catalyzed by CVS. 
The inventions illustratively described herein can suitably 
be practiced in the absence of any element or elements, limi-
tation or limitations, not specifically disclosed herein. Thus, 
for example, the terms "comprising," "including," "contain-
ing," etc. shall be read expansively and without limitation. 
Company (FIG. 9). 
The dominance of valencene as a reaction product under 
these conditions was sufficient to classify the C. paradisi 
eDNA as citrus valencene synthase, CVS. However, the 30 
amount of germacrene A, a putative reaction intermediate 
(FIG.1), generated by the CVS enzyme was atypical relative 
to previous studies with TEAS and HPS. Neither of these 
enzymes release appreciable amounts of reaction intermedi-
35 
ates. Further consideration of the acidic conditions likely to 
Additionally, the terms and expressions employed herein 
have been used as terms of description and not of limitation, 
and there is no intention in the use of such terms and expres-
sions of excluding any equivalents of the future shown and 
described or any portion thereof, and it is recognized that exist within juice vesicles/sacs where sesquiterpenes accu-
mulate in citrus fruit suggested that the CVS enzyme might 
have a pH optimal different from other terpene synthases. 
As shown in FIG. 10, virtually no germacrene A was 
detected as a reaction product between pH 6.0 to 7.0, with 
optimal valencene biosynthesis occurring at pH 7. 0 (FIG. 1 0). 
In contrast, germacrene A biosynthesis was optimal at pH 8.5 
with a relatively sharp transition point from valence as the 
dominate reaction product to germacrene A at pH 8.0. 
Example 4 
pH Dependence Assays 
Reactions to determine pH dependence were performed in 
glass GC-vials with 100 nM of purified enzyme, 20 mM 
MgC12, 50 f.LM FPP (Echelon; Salt Lake City, Utah), and 100 
mM buffer at various pH values; total reaction volume 500 
f.LL. The buffers were chosen within one pH unit of the buff-
er'spKa (pH 5-5.5, acetate; pH 6-7, MES; pH 7.5-9, Tris; pH 
9.5-10, ethanolamine; pH 10.5, CAPS). Reactions were 
allowed to proceed at room temperature for 30 min prior to 
overlaying with 500 f.LL of ethylacetate, vortexing for 10 sec, 
then direct analysis of the reaction products using an HP 6890 
gas chromatograph with a 5973 mass spectrometer (Agilent 
Technologies, Palo Alto, Calif.) with an auto-sampler pro-
grammed to remove 1 f.LL samples only from the organic 
phase. GC separations were performed on a 5%-phenyl-me-
thylpolysiloxane column (J&W Scientific, Folsom, Calif.) of 
various modifications are possible within the scope of the 
invention claimed. Thus, it should be understood that 
40 
although the present invention has been specifically disclosed 
by preferred embodiments and optional features, modifica-
tion and variation of the inventions herein disclosed can be 
resorted by those skilled in the art, and that such modifica-
tions and variations are considered to be within the scope of 
45 the inventions disclosed herein. The inventions have been 
described broadly and generically herein. Each of the nar-
rower species and subgeneric groupings falling within the 
scope of the generic disclosure also form part of these inven-
50 
tions. This includes the generic description of each invention 
with a proviso or negative limitation removing any subject 
matter from the genus, regardless of whether or not the 
excised materials specifically resided therein. 
In addition, where features or aspects of an invention are 
55 described in terms of the Markush group, those schooled in 
the art will recognize that the invention is also thereby 
described in terms of any individual member or subgroup of 
members of the Markush group. It is also to be understood 
that the above description is intended to be illustrative and not 
60 restrictive. Many embodiments will be apparent to those of in 
the art upon reviewing the above description. The scope of the 
invention should therefore, be determined not with reference 
to the above description, but should instead be determined 
with reference to the appended claims, along with the full 
65 scope of equivalents to which such claims are entitled. The 
disclosures of all articles and references, including patent 
publications, are incorporated herein by reference. 
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SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS, 8 
<210> SEQ ID NO 1 
<211> LENGTH, 1647 
<212> TYPE, DNA 
<213> ORGANISM, Citrus X paradisi 
<400> SEQUENCE, 1 
atgtcgtctg gagaaacatt tcgtcctact gcagatttcc atcctagttt atggagaaac 60 
catttcctca aaggtgcttc tgatttcaag acagttgatc atactgcaac tcaagaacga 120 
cacgaggcac tgaaagaaga ggtaaggaga atgataacag atgctgaaga taagcctgtt 180 
cagaagttac gcttgattga tgaagtacaa cgcctggggg tggcttatca ctttgagaaa 240 
gaaatagaag atgcaatact aaaattatgt ccaatctata ttgacagtaa tagagctgat 300 
ctccacaccg tttcccttca ttttcgattg cttaggcagc aaggaatcaa gatttcatgt 360 
gatgtgtttg agaagttcaa agatgatgag ggtagattca agtcatcgtt gataaacgat 420 
gttcaaggga tgttaagttt gtacgaggca gcatacatgg cagttcgcgg agaacatata 480 
ttagatgaag ccattgcttt cactaccact cacctgaagt cattggtagc tcaggatcat 540 
gtaaccccta agcttgcgga acagataaat catgctttat accgtcctct tcgtaaaacc 600 
ctaccaagat tagaggcgag gtattttatg tccatgatca attcaacaag tgatcattta 660 
tacaataaaa ctctgctgaa ttttgcaaag ttagatttta acatattgct agagccgcac 720 
aaggaggaac tcaatgaatt aacaaagtgg tggaaagatt tagacttcac tacaaaacta 780 
ccttatgcaa gagacagatt agtggagtta tatttttggg atttagggac atacttcgag 840 
cctcaatatg catttgggag aaagataatg acccaattaa attacatatt atccatcata 900 
gatgatactt atgatgcgta tggtacactt gaagaactca gcctctttac tgaagcagtt 960 
caaagatgga atattgaggc cgtagatatg cttccagaat acatgaaatt gatttacagg 1020 
acactcttag atgcttttaa tgaaattgag gaagatatgg ccaagcaagg aagatcacac 1080 
tgcgtacgtt atgcaaaaga ggagaatcaa aaagtaattg gagcatactc tgttcaagcc 1140 
aaatggttca gtgaaggtta cgttccaaca attgaggagt atatgcctat tgcactaaca 1200 
agttgtgctt acacattcgt cataacaaat tccttccttg gcatgggtga ttttgcaact 1260 
aaagaggttt ttgaatggat ctccaataac cctaaggttg taaaagcagc atcagttatc 1320 
tgcagactca tggatgacat gcaaggtcat gagtttgagc agaagagagg acatgttgcg 1380 
tcagctattg aatgttacac gaagcagcat ggtgtctcta aggaagaggc aattaaaatg 1440 
tttgaagaag aagttgcaaa tgcatggaaa gatattaacg aggagttgat gatgaagcca 1500 
accgtcgttg cccgaccact gctcgggacg attcttaatc ttgctcgtgc aattgatttt 1560 
atttacaaag aggacgacgg ctatacgcat tcttacctaa ttaaagatca aattgcttct 1620 
gtgctaggag accacgttcc attttga 1647 
<210> SEQ ID NO 2 
<211> LENGTH, 35 
<212> TYPE, DNA 
<213> ORGANISM, Citrus X paradisi 
<400> SEQUENCE, 2 
ggggaattca tctggtctgg agaaacattt cgtcc 35 
US 7,442,785 B2 
<210> SEQ ID NO 3 
<211> LENGTH, 36 
<212> TYPE, DNA 
25 
<213> ORGANISM, Citrus X paradisi 
<400> SEQUENCE, 3 
ccgctcgagg aagtatagaa ctagtcgtca aaatgg 
<210> SEQ ID NO 4 
<211> LENGTH, 548 
<212> TYPE, PRT 
<213> ORGANISM, Citrus X paradisi 
<400> SEQUENCE, 4 
-continued 
Met Ser Ser Gly Glu Thr Phe Arg Pro Thr Ala Asp Phe His Pro Ser 
1 5 10 15 
Leu Trp Arg Asn His Phe Leu Lys Gly Ala Ser Asp Phe Lys Thr Val 
20 25 30 
Asp His Thr Ala Thr Gln Glu Arg His Glu Ala Leu Lys Glu Glu Val 
35 40 45 
Arg Arg Met Ile Thr Asp Ala Glu Asp Lys Pro Val Gln Lys Leu Arg 
50 55 60 
Leu Ile Asp Glu Val Gln Arg Leu Gly Val Ala Tyr His Phe Glu Lys 
65 70 75 80 
Glu Ile Glu Asp Ala Ile Leu Lys Leu Cys Pro Ile Tyr Ile Asp Ser 
85 90 95 
Asn Arg Ala Asp Leu His Thr Val Ser Leu His Phe Arg Leu Leu Arg 
100 105 110 
Gln Gln Gly Ile Lys Ile Ser Cys Asp Val Phe Glu Lys Phe Lys Asp 
115 120 125 
Asp Glu Gly Arg Phe Lys Ser Ser Leu Ile Asn Asp Val Gln Gly Met 
130 135 140 
Leu Ser Leu Tyr Glu Ala Ala Tyr Met Ala Val Arg Gly Glu His Ile 
145 150 155 160 
Leu Asp Glu Ala Ile Ala Phe Thr Thr Thr His Leu Lys Ser Leu Val 
165 170 175 
Ala Gln Asp His Val Thr Pro Lys Leu Ala Glu Gln Ile Asn His Ala 
180 185 190 
Leu Tyr Arg Pro Leu Arg Lys Thr Leu Pro Arg Leu Glu Ala Arg Tyr 
195 200 205 
Phe Met Ser Met Ile Asn Ser Thr Ser Asp His Leu Tyr Asn Lys Thr 
210 215 220 
Leu Leu Asn Phe Ala Lys Leu Asp Phe Asn Ile Leu Leu Glu Pro His 
225 230 235 240 
Lys Glu Glu Leu Asn Glu Leu Thr Lys Trp Trp Lys Asp Leu Asp Phe 
245 250 255 
Thr Thr Lys Leu Pro Tyr Ala Arg Asp Arg Leu Val Glu Leu Tyr Phe 
260 265 270 
Trp Asp Leu Gly Thr Tyr Phe Glu Pro Gln Tyr Ala Phe Gly Arg Lys 
275 280 285 
Ile Met Thr Gln Leu Asn Tyr Ile Leu Ser Ile Ile Asp Asp Thr Tyr 
290 295 300 
Asp Ala Tyr Gly Thr Leu Glu Glu Leu Ser Leu Phe Thr Glu Ala Val 
305 310 315 320 
Gln Arg Trp Asn Ile Glu Ala Val Asp Met Leu Pro Glu Tyr Met Lys 
325 330 335 
26 
36 
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-continued 
Leu Ile Tyr Arg Thr Leu Leu Asp Ala Phe Asn Glu Ile Glu Glu Asp 
340 345 350 
Met Ala Lys Gln Gly Arg Ser His Cys Val Arg Tyr Ala Lys Glu Glu 
355 360 365 
Asn Gln Lys Val Ile Gly Ala Tyr Ser Val Gln Ala Lys Trp Phe Ser 
370 375 380 
Glu Gly Tyr Val Pro Thr Ile Glu Glu Tyr Met Pro Ile Ala Leu Thr 
385 390 395 400 
Ser Cys Ala Tyr Thr Phe Val Ile Thr Asn Ser Phe Leu Gly Met Gly 
405 410 415 
Asp Phe Ala Thr Lys Glu Val Phe Glu Trp Ile Ser Asn Asn Pro Lys 
420 425 430 
Val Val Lys Ala Ala Ser Val Ile Cys Arg Leu Met Asp Asp Met Gln 
435 440 445 
Gly His Glu Phe Glu Gln Lys Arg Gly His Val Ala Ser Ala Ile Glu 
450 455 460 
Cys Tyr Thr Lys Gln His Gly Val Ser Lys Glu Glu Ala Ile Lys Met 
465 470 475 480 
Phe Glu Glu Glu Val Ala Asn Ala Trp Lys Asp Ile Asn Glu Glu Leu 
485 490 495 
Met Met Lys Pro Thr Val Val Ala Arg Pro Leu Leu Gly Thr Ile Leu 
500 505 510 
Asn Leu Ala Arg Ala Ile Asp Phe Ile Tyr Lys Glu Asp Asp Gly Tyr 
515 520 525 
Thr His Ser Tyr Leu Ile Lys Asp Gln Ile Ala Ser Val Leu Gly Asp 
530 535 540 
His Val Pro Phe 
545 
<210> SEQ ID NO 5 
<211> LENGTH, 1647 
<212> TYPE, DNA 
<213> ORGANISM, Citrus X paradisi 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1) .. (789) 
<223> OTHER INFORMATION, n is a, 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (793) .. (816) 
<223> OTHER INFORMATION, n is a, 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (820) .. (1206) 
<223> OTHER INFORMATION, n is a, 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1213) .. (1320) 
<223> OTHER INFORMATION, n is a, 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1324) .. (1332) 
<223> OTHER INFORMATION, n is a, 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, ( 1336) .. ( 1563) 
<223> OTHER INFORMATION, n is a, 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1567) .. (1575) 
<223> OTHER INFORMATION, n is a, 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1579) .. (1581) 
c, g, or t 
c, g, or t 
c, g, or t 
c, g, or t 
c, g, or t 
c, g, or t 
c, g, or t 
28 
29 
<223> OTHER INFORMATION, n is a, c, g, or t 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1588) .. (1647) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<400> SEQUENCE, 5 
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nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnna gannnnnnnn nnnnnnnnnn nnnnnntggn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnngctt acnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
tgcnnnnnnn nngatnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnntacnnnn nnnnngacnn ntatacgnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn nnnnnnn 
<210> SEQ ID NO 6 
<211> LENGTH, 1647 
<212> TYPE, DNA 
<213> ORGANISM, Citrus X paradisi 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1) .. (36) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (40) .. (795) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
30 
60 
120 
180 
240 
300 
360 
420 
480 
540 
600 
660 
720 
780 
840 
900 
960 
1020 
1080 
1140 
1200 
1260 
1320 
1380 
1440 
1500 
1560 
1620 
1647 
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-continued 
<222> LOCATION, (799) .. (807) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (811) .. (891) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (895) .. (903) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (907) .. (1113) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1117) .. (1125) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1129) .. (1200) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1207) .. (1218) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1222) .. (1308) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1312) .. (1323) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1327) .. (1335) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1339) .. (1344) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1348) .. (1539) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1543) .. (1548) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1555) .. ( 1560) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1564) .. (1587) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1591) .. ( 1647) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<400> SEQUENCE, 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnttcn nnnnnnnnnn nnnnnnnnnn 60 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 120 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 180 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 240 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 300 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 360 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 420 
nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnagann 
nnnnnnnnnn nnnnnnnnnn 
nnngatnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn 
agttgtnnnn nnnnnnnngt 
nnnnnnnnnn nnnnnnnnnn 
nnnagannnn nnnnngacnn 
nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn 
attnnnnnnn nnnnnnnnnn 
nnnnnnnnnn nnnnnnnnnn 
<210> SEQ ID NO 7 
<211> LENGTH, 548 
<212> TYPE, PRT 
33 
nnnnnnnnnn 
nnnnnnnnnn 
nnnnnnnnnn 
nnnnnnnnnn 
nnnnnnnnnn 
nnnnnnnnnn 
nnnnnnntta 
nnnnnnnnnn 
nnnnnnnnnn 
nnnnnnnnnn 
nnnnnnnnnn 
nnnnnnnnnn 
nnnnnnnnnn 
cnnnnnnnnn 
nnnnnnnnnn 
nnnnggtnnn 
nnnnnnnnnn 
nnnnnnnnnn 
nnnnnnnnnn 
nnnnnnncat 
nnnnnnn 
<213> ORGANISM, Citrus X paradisi 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1) .. (263) 
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-continued 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 480 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 540 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 600 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 660 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 720 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 780 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 840 
nnnnnnnnnn nnnnnnnnnn ntccnnnnnn 900 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 960 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 1020 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 1080 
nnngtannnn nnnnntacnn nnnnnnnnnn 1140 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 1200 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 1260 
nnnnnnnnnn nnnnnnnngc annnnnnnnn 1320 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 1380 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 1440 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 1500 
nnnnnnnnnc ttnnnnnngc aattnnnnnn 1560 
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 1620 
1647 
<223> OTHER INFORMATION, Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (265) .. (272) 
<223> OTHER INFORMATION, Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (274) .. (402) 
<223> OTHER INFORMATION, Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (405) .. (440) 
<223> OTHER INFORMATION, Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (442) .. (444) 
<223> OTHER INFORMATION, Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (446) .. (521) 
<223> OTHER INFORMATION, Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (523) .. (525) 
<223> OTHER INFORMATION, Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (527) .. (527) 
<223> OTHER INFORMATION, Xaa can be any naturally occurring amino acid 
34 
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<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (530) .. (548) 
-continued 
<223> OTHER INFORMATION, Xaa can be any naturally occurring amino acid 
<400> SEQUENCE, 7 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1 5 10 15 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
20 25 30 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
35 40 45 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
50 55 60 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
65 70 75 80 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
85 90 95 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
100 105 110 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
115 120 125 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
130 135 140 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
145 150 155 160 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
165 170 175 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
180 185 190 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
195 200 205 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
210 215 220 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
225 230 235 240 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
245 250 255 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
260 265 270 
Trp Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
275 280 285 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
290 295 300 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
305 310 315 320 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
325 330 335 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
340 345 350 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
355 360 365 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
370 375 380 
36 
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-continued 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
385 390 395 400 
Xaa Xaa Ala Tyr Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
405 410 415 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
420 425 430 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Asp Xaa Xaa Xaa 
435 440 445 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
450 455 460 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
465 470 475 480 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
485 490 495 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
500 505 510 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Tyr Xaa Xaa Xaa Asp Xaa Tyr 
515 520 525 
Thr Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
530 535 540 
Xaa Xaa Xaa Xaa 
545 
<210> SEQ ID NO 8 
<211> LENGTH, 548 
<212> TYPE, PRT 
<213> ORGANISM, Citrus X paradisi 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1) .. (12) 
<223> OTHER INFORMATION, Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (14) .. (265) 
<223> OTHER INFORMATION, Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (267) .. (269) 
<223> OTHER INFORMATION, Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (271) .. (297) 
<223> OTHER INFORMATION, Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (299) .. (301) 
<223> OTHER INFORMATION, Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (303) .. (371) 
<223> OTHER INFORMATION, Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (373) .. (375) 
<223> OTHER INFORMATION, Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (377) .. (400) 
<223> OTHER INFORMATION, Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (403) .. (406) 
<223> OTHER INFORMATION, Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (408) .. (436) 
<223> OTHER INFORMATION, Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
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-continued 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (438) .. (441) 
<223> OTHER INFORMATION, Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (443) .. (445) 
<223> OTHER INFORMATION, Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (447) .. (448) 
<223> OTHER INFORMATION, Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (450) .. (513) 
<223> OTHER INFORMATION, Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (515) .. (516) 
<223> OTHER INFORMATION, Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (519) .. (520) 
<223> OTHER INFORMATION, Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (522) .. (529) 
<223> OTHER INFORMATION, Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (531) .. (548) 
<223> OTHER INFORMATION, Xaa can be any naturally occurring amino acid 
<400> SEQUENCE, 8 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Phe Xaa Xaa Xaa 
1 5 10 15 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
20 25 30 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
35 40 45 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
50 55 60 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
65 70 75 80 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
85 90 95 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
100 105 110 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
115 120 125 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
130 135 140 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
145 150 155 160 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
165 170 175 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
180 185 190 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
195 200 205 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
210 215 220 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
225 230 235 240 
40 
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-continued 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
245 250 255 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Arg Xaa Xaa Xaa Leu Xaa Xaa 
260 265 270 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
275 280 285 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Ser Xaa Xaa Xaa Asp Xaa Xaa 
290 295 300 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
305 310 315 320 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
325 330 335 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
340 345 350 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
355 360 365 
Xaa Xaa Xaa Val Xaa Xaa Xaa Tyr Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
370 375 380 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
385 390 395 400 
Ser Cys Xaa Xaa Xaa Xaa Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
405 410 415 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
420 425 430 
Xaa Xaa Xaa Xaa Ala Xaa Xaa Xaa Xaa Arg Xaa Xaa Xaa Asp Xaa Xaa 
435 440 445 
Gly Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
450 455 460 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
465 470 475 480 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
485 490 495 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
500 505 510 
Xaa Leu Xaa Xaa Ala Ile Xaa Xaa Ile Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
515 520 525 
Xaa His Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
530 535 540 
Xaa Xaa Xaa Xaa 
545 
42 
We claim: 
1. An isolated nucleic acid comprising the nucleic acid 
55 
sequence of SEQ ID NO: 1. 
3. An isolated nucleic acid that encodes the amino acid 
sequence of SEQ ID NO: 4. 
2. The isolated nucleic acid of claim 1 wherein the nucleic 
acid is DNA. 
4. The isolated nucleic acid of claim 3 wherein the nucleic 
acid is DNA. 
* * * * * 
